Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:INSM NASDAQ:JAZZ NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$103.02+1.6%$105.84$72.21▼$139.13$4.99B0.51635,684 shs838,764 shsINSMInsmed$108.69+1.3%$93.59$60.40▼$108.89$20.35B0.92.33 million shs2.26 million shsJAZZJazz Pharmaceuticals$115.52+0.8%$110.92$95.49▼$148.06$6.94B0.32582,660 shs598,949 shsSMMTSummit Therapeutics$27.07+2.7%$23.35$8.88▼$36.91$19.58B-1.012.68 million shs1.92 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+1.62%+2.17%-0.86%-8.19%+17.99%INSMInsmed+1.31%+4.56%+10.64%+50.33%+49.40%JAZZJazz Pharmaceuticals+0.78%-2.29%+5.09%-3.77%+4.78%SMMTSummit Therapeutics+2.65%-5.58%+19.67%-2.97%+150.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.8236 of 5 stars4.53.00.04.52.94.20.6INSMInsmed3.768 of 5 stars2.53.00.04.33.21.70.6JAZZJazz Pharmaceuticals4.8537 of 5 stars4.52.00.04.02.33.32.5SMMTSummit Therapeutics3.0125 of 5 stars4.42.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.06Buy$172.3367.28% UpsideINSMInsmed 3.00Buy$109.200.47% UpsideJAZZJazz Pharmaceuticals 2.93Moderate Buy$181.6457.24% UpsideSMMTSummit Therapeutics 2.79Moderate Buy$34.6728.06% UpsideCurrent Analyst Ratings BreakdownLatest AXSM, JAZZ, SMMT, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$119.00 ➝ $130.007/22/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$166.00 ➝ $165.007/17/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$102.00 ➝ $108.007/15/2025JAZZJazz PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$152.007/8/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.007/3/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$190.007/1/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.007/1/2025SMMTSummit TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M13.15N/AN/A$1.18 per share87.31INSMInsmed$381.03M54.12N/AN/A$1.60 per share67.93JAZZJazz Pharmaceuticals$4.06B1.72$30.56 per share3.78$67.72 per share1.71SMMTSummit TherapeuticsN/AN/AN/AN/A$0.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A36.53N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)INSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/7/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M$7.5015.406.175.5111.86%26.62%9.14%8/5/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest AXSM, JAZZ, SMMT, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INSMInsmed-$1.31N/AN/AN/A$104.06 millionN/A8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61N/AN/AN/A$1.05 billionN/A8/5/2025Q2 2025SMMTSummit Therapeutics-$0.10N/AN/AN/AN/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.04N/AN/AN/A$140.02 millionN/A5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.482.031.96INSMInsmed11.385.865.44JAZZJazz Pharmaceuticals1.283.382.97SMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%INSMInsmedN/AJAZZJazz Pharmaceuticals89.14%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%INSMInsmed3.00%JAZZJazz Pharmaceuticals4.30%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million38.26 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionableJAZZJazz Pharmaceuticals2,80060.51 million57.91 millionOptionableSMMTSummit Therapeutics110742.67 million112.14 millionOptionableAXSM, JAZZ, SMMT, and INSM HeadlinesRecent News About These CompaniesTD Asset Management Inc Reduces Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)July 31 at 4:51 AM | marketbeat.comSummit Therapeutics (SMMT) Projected to Post Earnings on TuesdayJuly 30 at 8:48 AM | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $1.28 Million Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 30 at 6:12 AM | marketbeat.comTrivest Advisors Ltd Acquires New Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 29, 2025 | marketbeat.comSummit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90July 28, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 27, 2025 | prnewswire.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives $34.67 Average Price Target from AnalystsJuly 27, 2025 | americanbankingnews.comIvyRock Asset Management HK Ltd Sells 74,759 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)July 26, 2025 | marketbeat.comLegato Capital Management LLC Takes Position in Summit Therapeutics PLC (NASDAQ:SMMT)July 26, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 22, 2025 | prnewswire.com3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsJuly 22, 2025 | fool.comThis Healthcare Stock's Revolutionary Drug Could Make Early Investors RichJuly 21, 2025 | finance.yahoo.comSargent Investment Group LLC Sells 70,000 Shares of Summit Therapeutics PLC (NASDAQ:SMMT)July 21, 2025 | marketbeat.comKingsview Wealth Management LLC Buys Shares of 46,337 Summit Therapeutics PLC (NASDAQ:SMMT)July 21, 2025 | marketbeat.com3 Monster Stocks in the Making to Buy Right NowJuly 20, 2025 | fool.comPrincipal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)July 18, 2025 | marketbeat.comSMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmJuly 17, 2025 | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 17, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?July 16, 2025 | marketbeat.comFlorida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)July 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, JAZZ, SMMT, and INSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$103.02 +1.64 (+1.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$104.02 +1.01 (+0.98%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Insmed NASDAQ:INSM$108.69 +1.41 (+1.31%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$108.80 +0.12 (+0.11%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Jazz Pharmaceuticals NASDAQ:JAZZ$115.52 +0.89 (+0.78%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$113.96 -1.56 (-1.35%) As of 08/1/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Summit Therapeutics NASDAQ:SMMT$27.07 +0.70 (+2.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$27.35 +0.28 (+1.03%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
